136 related articles for article (PubMed ID: 14718730)
1. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury.
Blennow K; Nellgård B
Neurology; 2004 Jan; 62(1):159; author reply 159-60. PubMed ID: 14718730
[No Abstract] [Full Text] [Related]
2. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury.
Franz G; Beer R; Kampfl A; Engelhardt K; Schmutzhard E; Ulmer H; Deisenhammer F
Neurology; 2003 May; 60(9):1457-61. PubMed ID: 12743231
[TBL] [Abstract][Full Text] [Related]
3. Can we rely only on ratios of cerebrospinal fluid biomarkers for AD biological diagnosis?
Lehmann S; Gabelle A; Paquet C
Alzheimers Dement; 2015 Sep; 11(9):1125-6. PubMed ID: 25457432
[No Abstract] [Full Text] [Related]
4. A cerebrospinal fluid biosignature for the diagnosis of Alzheimer's disease.
Barichello T; Giridharan VV; Dal-Pizzol F
Braz J Psychiatry; 2019; 41(6):467-468. PubMed ID: 31826090
[No Abstract] [Full Text] [Related]
5. Glaucoma progression associated with altered cerebral spinal fluid levels of amyloid beta and tau proteins.
Nucci C; Martucci A; Martorana A; Sancesario GM; Cerulli L
Clin Exp Ophthalmol; 2011 Apr; 39(3):279-81. PubMed ID: 20973903
[No Abstract] [Full Text] [Related]
6. Use of cerebrospinal fluid biomarkers for diagnosis of incipient Alzheimer disease in patients with mild cognitive impairment.
Dean RA; Shaw LM
Clin Chem; 2010 Jan; 56(1):7-9. PubMed ID: 19926774
[No Abstract] [Full Text] [Related]
7. Traumatic brain injury elevates the Alzheimer's amyloid peptide A beta 42 in human CSF. A possible role for nerve cell injury.
Emmerling MR; Morganti-Kossmann MC; Kossmann T; Stahel PF; Watson MD; Evans LM; Mehta PD; Spiegel K; Kuo YM; Roher AE; Raby CA
Ann N Y Acad Sci; 2000 Apr; 903():118-22. PubMed ID: 10818496
[TBL] [Abstract][Full Text] [Related]
8. Medication use as a confounding factor in the use of the cerebrospinal fluid tau/beta-amyloid42 ratio.
Wong V
Arch Neurol; 2007 Sep; 64(9):1357; author reply 1357-9. PubMed ID: 17846282
[No Abstract] [Full Text] [Related]
9. Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease.
Kristofikova Z; Ricny J; Kolarova M; Vyhnalek M; Hort J; Laczo J; Sirova J; Ripova D
J Alzheimers Dis; 2014; 42 Suppl 3():S91-8. PubMed ID: 24670397
[TBL] [Abstract][Full Text] [Related]
10. The role of amyloid-β, tau, and apolipoprotein E epsilon4 in Alzheimer disease: how is the team playing?
Filippi M; Canu E; Agosta F
AJNR Am J Neuroradiol; 2013 Mar; 34(3):511-2. PubMed ID: 22918432
[No Abstract] [Full Text] [Related]
11. Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.
Marksteiner J; Hinterhuber H; Humpel C
Drugs Today (Barc); 2007 Jun; 43(6):423-31. PubMed ID: 17612711
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.
Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Otto M; Kornhuber J; Rüther E; Wiltfang J
Dement Geriatr Cogn Disord; 2011; 31(1):37-44. PubMed ID: 21135556
[TBL] [Abstract][Full Text] [Related]
13. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
[TBL] [Abstract][Full Text] [Related]
14. LOW specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate alzheimer's disease from vascular dementia.
Le Bastard N; Van Buggenhout M; De Leenheir E; Martin JJ; De Deyn PP; Engelborghs S
J Gerontol A Biol Sci Med Sci; 2007 Aug; 62(8):923-4; author reply 924-5. PubMed ID: 17702886
[No Abstract] [Full Text] [Related]
15. Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis.
Renard D; Gabelle A; Hirtz C; Demattei C; Thouvenot E; Lehmann S
J Alzheimers Dis; 2016 Oct; 54(4):1291-1295. PubMed ID: 27567848
[TBL] [Abstract][Full Text] [Related]
16. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
[TBL] [Abstract][Full Text] [Related]
17. [Searched for and found: non-demented patients with Alzheimer's disease].
Engelborghs S
Tijdschr Psychiatr; 2011; 53(9):654-6. PubMed ID: 21898323
[No Abstract] [Full Text] [Related]
18. Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort.
Wang ML; Wei XE; Yu MM; Li PY; Li WB;
Neurosci Lett; 2017 Aug; 655():115-120. PubMed ID: 28689050
[TBL] [Abstract][Full Text] [Related]
19. Dissociation of cerebrospinal fluid amyloid-β and tau levels in patients with prolonged posttraumatic disorders of consciousness.
Bagnato S; Andriolo M; Boccagni C; Sant'Angelo A; D'Ippolito ME; Galardi G
Brain Inj; 2018; 32(8):1056-1060. PubMed ID: 29792528
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid biomarkers for Alzheimer's disease: more to come?
Zetterberg H; Blennow K
J Alzheimers Dis; 2013; 33 Suppl 1():S361-9. PubMed ID: 22710917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
